Bonney Michael W
Director at ALNY; Chief Executive Officer at CUBIST PHARMACEUTICALS INC; Director at NPS PHARMACEUTICALS INC
- Sold, on record
- $42.3M
- Dollars the filings state
- Form 4 sales
- 18
- Latest Aug 18, 2025
- Form 144 notices
- 3
- Proposed sales
- Companies
- 3
- Filed as an executive or holder
Companies
- ALNYALNYLAM PHARMACEUTICALS, INC.Director
- CUBIST PHARMACEUTICALS INCChief Executive Officer
- NPS PHARMACEUTICALS INCDirector
Sales by reason
3
Routine
8
Plan not stated
0
No plan
7
Unusual
Form 4 sales per year, every sale on record.
Sales by company
- CUBIST PHARMACEUTICALS INC626,292 shares
- ALNY58,948 shares
- NPS PHARMACEUTICALS INC5,325 shares
Shares sold, every Form 4 sale on record.
Timeline
- Aug 18, 2025Routine
Sold 40.1% of their holdings
$5.1M11,250 shares at $450.00
- Aug 18, 2025Notice
Filed a notice to sell 11,250 shares
$5.1M11,250 shares
- May 15, 2025Routine
Sold 40.1% of their holdings
$3.1M11,250 shares at $277.71
- May 15, 2025Notice
Filed a notice to sell 11,250 shares
$3M11,250 shares
- Dec 27, 2023Routine
Sold 65.2% of their holdings
$5.8M30,000 shares at $195.00
- Dec 27, 2023Notice
Filed a notice to sell 30,000 shares
$5.7M30,000 shares
- Aug 3, 2023Unusual
Sold 28.7% of their holdings
$1.2M6,448 shares at $185.38
- May 15, 2014Plan not stated
Sold 1.7% of their holdings
$205k3,036 shares at $67.50
- May 14, 2014Plan not stated
Sold 2.2% of their holdings
$265k3,840 shares at $69.00
- Feb 27, 2014Unusual
Sold 37.2% of their holdings
$8.1M100,000 shares at $81.25
10 of 21
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Jul 1, 2026 | AUTL | Director | AwardedRestricted Share Units | 79,167 | 47,500 | SEC | ||
| Jun 29, 2026 | Jun 29, 2026 | IMUX | Director | AwardedStock Option | 100,000 | 100,000 | SEC | ||
| Aug 18, 2025 | Aug 19, 2025 | ALNY | Director | Sold | 11,250 | $450.00 | $5.1M | 16,804 | SEC |
| Aug 18, 2025 | Aug 19, 2025 | ALNY | Director | Exercised or settledStock Option (right to buy) | 11,250 | 0 | SEC | ||
| Aug 18, 2025 | Aug 19, 2025 | ALNY | Director | Exercised options | 11,250 | $70.20 | $790k | 28,054 | SEC |
| May 15, 2025 | May 19, 2025 | ALNY | Director | Sold | 11,250 | $277.71 | $3.1M | 16,804 | SEC |
| May 15, 2025 | May 19, 2025 | ALNY | Director | Exercised or settledStock Option (right to buy) | 11,250 | 0 | SEC | ||
| May 15, 2025 | May 19, 2025 | ALNY | Director | Exercised options | 11,250 | $131.21 | $1.5M | 28,054 | SEC |
| May 8, 2025 | May 12, 2025 | ALNY | Director | AwardedStock Option (right to buy) | 1,558 | 1,558 | SEC | ||
| May 8, 2025 | May 12, 2025 | ALNY | Director | Awarded | 775 | 16,804 | SEC | ||
| May 16, 2024 | May 20, 2024 | ALNY | Director | AwardedStock Option (right to buy) | 5,228 | 5,228 | SEC | ||
| Dec 27, 2023 | Dec 29, 2023 | ALNY | Director | Sold | 30,000 | $195.00 | $5.8M | 16,029 | SEC |
| Dec 27, 2023 | Dec 29, 2023 | ALNY | Director | Exercised or settledStock Option (right to buy) | 30,000 | 0 | SEC | ||
| Dec 27, 2023 | Dec 29, 2023 | ALNY | Director | Exercised options | 30,000 | $96.45 | $2.9M | 46,029 | SEC |
| Aug 3, 2023 | Aug 4, 2023 | ALNY | Director | Sold | 6,448 | $185.38 | $1.2M | 16,029 | SEC |
| Aug 2, 2023 | Aug 4, 2023 | ALNY | Director | Exercised or settledRestricted Stock Units | 22,477 | 0 | SEC | ||
| Aug 2, 2023 | Aug 4, 2023 | ALNY | Director | Exercised options | 22,477 | 22,477 | SEC | ||
| May 18, 2023 | May 19, 2023 | ALNY | Director | AwardedStock Option (right to buy) | 3,454 | 3,454 | SEC | ||
| Aug 2, 2021 | Aug 3, 2021 | ALNY | Executive Chair | AwardedRestricted Stock Units | 22,477 | 22,477 | SEC | ||
| Jul 15, 2021 | Jul 19, 2021 | ALNY | Director | AwardedStock Option (right to buy) | 4,032 | 4,032 | SEC | ||
| Jun 30, 2021 | Jul 1, 2021 | Kaleido Biosciences, Inc. | Director | AwardedStock Option (Right to Buy) | 30,000 | 15,000 | SEC | ||
| Jun 30, 2021 | Jul 1, 2021 | BMY | Director | AwardedDeferred Share Units | 345 | 9,342 | SEC | ||
| Jun 13, 2021 | Jun 14, 2021 | BMY | Director | Exercised or settledRestricted Stock Units | 902 | 0 | SEC | ||
| Jun 13, 2021 | Jun 14, 2021 | BMY | Director | Exercised options | 902 | 12,501 | SEC | ||
| Jun 3, 2021 | Jun 4, 2021 | BMY | Director | Exercised or settledRestricted Stock Units | 2,949 | 2,949 | SEC | ||
| Jun 3, 2021 | Jun 4, 2021 | BMY | Director | Exercised options | 2,949 | 11,599 | SEC | ||
| Jun 1, 2021 | Jun 3, 2021 | DNTH | Director | AwardedStock Option (Right to Buy) | 18,188 | 18,188 | SEC | ||
| Mar 31, 2021 | Apr 2, 2021 | BMY | Director | AwardedDeferred Share Units | 366 | $63.13 | $23k | 8,930 | SEC |
| Feb 1, 2021 | Feb 3, 2021 | BMY | Director | AwardedDeferred Share Units | 3,054 | $62.21 | $190k | 8,565 | SEC |
| Dec 31, 2020 | Jan 5, 2021 | BMY | Director | AwardedDeferred Share Units | 372 | $62.03 | $23k | 5,468 | SEC |
| Sep 30, 2020 | Oct 2, 2020 | BMY | Director | AwardedDeferred Share Units | 383 | $60.29 | $23k | 5,057 | SEC |
| Jul 1, 2020 | Jul 6, 2020 | ALNY | Director | AwardedStock Option (right to buy) | 4,581 | 4,581 | SEC | ||
| Jun 30, 2020 | Jul 1, 2020 | Kaleido Biosciences, Inc. | Director | AwardedStock Option (Right to Buy) | 15,000 | 15,000 | SEC | ||
| Jun 30, 2020 | Jul 2, 2020 | BMY | Director | AwardedDeferred Share Units | 392 | $58.80 | $23k | 4,639 | SEC |
| Jun 14, 2020 | Jun 16, 2020 | BMY | Director | Exercised or settledRestricted Stock Units | 1,461 | 0 | SEC | ||
| Jun 14, 2020 | Jun 16, 2020 | BMY | Director | Exercised options | 1,461 | 8,650 | SEC | ||
| Jun 5, 2020 | Jun 9, 2020 | DNTH | Director | AwardedStock Option (Right to Buy) | 18,188 | 18,188 | SEC | ||
| Jun 3, 2020 | Jun 5, 2020 | BMY | Director | Exercised or settledRestricted Stock Units | 2,949 | 5,898 | SEC | ||
| Jun 3, 2020 | Jun 5, 2020 | BMY | Director | Exercised options | 2,949 | 7,189 | SEC | ||
| Mar 31, 2020 | Apr 2, 2020 | BMY | Director | AwardedDeferred Share Units | 414 | $55.74 | $23k | 4,215 | SEC |
| Feb 28, 2020 | Feb 28, 2020 | SRPT | Director | AwardedStock option (right to buy) | 3,685 | 3,685 | SEC | ||
| Feb 28, 2020 | Feb 28, 2020 | SRPT | Director | Awarded | 2,075 | 9,126 | SEC | ||
| Feb 1, 2020 | Feb 4, 2020 | BMY | Director | AwardedDeferred Share Units | 3,018 | $62.95 | $190k | 3,801 | SEC |
| Dec 31, 2019 | Jan 3, 2020 | BMY | Director | AwardedDeferred Share Units | 126 | $64.19 | $8k | 782 | SEC |
| Dec 4, 2019 | Jun 9, 2020 | BMY | Director | Bought | 88 | $58.90 | $5k | 7,189 | SEC |
| Nov 20, 2019 | Nov 22, 2019 | CELGENE CORP /DE/ | Director | Returned to the companyStock Option (right to buy) | 61,792 | 0 | SEC | ||
| Nov 20, 2019 | Nov 22, 2019 | CELGENE CORP /DE/ | Director | Returned to the company | 4,209 | 0 | SEC | ||
| Nov 20, 2019 | Nov 22, 2019 | BMY | Director | AwardedDeferred Share Units | 656 | $56.41 | $37k | 656 | SEC |
| Sep 9, 2019 | Sep 9, 2019 | SRPT | Director | Bought | 2,000 | $86.74 | $173k | 7,051 | SEC |
| Jul 1, 2019 | Jul 2, 2019 | ALNY | Director | AwardedStock Option (right to buy) | 9,000 | 9,000 | SEC |
Page 1
Sales and notices (21)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | Aug 19, 2025 | ALNY | Director | Form 4 sale | 11,250 | $5.1M | 40.1% | Routine | SEC |
| Aug 18, 2025 | Aug 18, 2025 | ALNY | Director | Form 144 notice | 11,250 | $5.1M | Notice | SEC | |
| May 15, 2025 | May 19, 2025 | ALNY | Director | Form 4 sale | 11,250 | $3.1M | 40.1% | Routine | SEC |
| May 15, 2025 | May 15, 2025 | ALNY | Director | Form 144 notice | 11,250 | $3M | Notice | SEC | |
| Dec 27, 2023 | Dec 29, 2023 | ALNY | Director | Form 4 sale | 30,000 | $5.8M | 65.2% | Routine | SEC |
| Dec 27, 2023 | Dec 27, 2023 | ALNY | Director | Form 144 notice | 30,000 | $5.7M | Notice | SEC | |
| Aug 3, 2023 | Aug 4, 2023 | ALNY | Director | Form 4 sale | 6,448 | $1.2M | 28.7% | Unusual | SEC |
| May 15, 2014 | May 15, 2014 | CUBIST PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 3,036 | $205k | 1.7% | Plan not stated | SEC |
| May 14, 2014 | May 14, 2014 | CUBIST PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 3,840 | $265k | 2.2% | Plan not stated | SEC |
| Feb 27, 2014 | Feb 28, 2014 | CUBIST PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 100,000 | $8.1M | 37.2% | Unusual | SEC |
| Feb 20, 2014 | Feb 21, 2014 | CUBIST PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 3,112 | $235k | 1.8% | Plan not stated | SEC |
| May 20, 2013 | May 22, 2013 | CUBIST PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 60,000 | $3M | 27.1% | Unusual | SEC |
| May 16, 2013 | May 17, 2013 | CUBIST PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 2,400 | $115k | 1.5% | Plan not stated | SEC |
| May 15, 2013 | May 16, 2013 | CUBIST PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 2,979 | $144k | 1.8% | Plan not stated | SEC |
| May 14, 2013 | May 15, 2013 | CUBIST PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 3,753 | $185k | 2.4% | Plan not stated | SEC |
| Feb 7, 2013 | Feb 11, 2013 | NPS PHARMACEUTICALS INC | Director | Form 4 sale | 5,325 | $47k | 27.7% | Unusual | SEC |
| Jan 29, 2013 | Jan 30, 2013 | CUBIST PHARMACEUTICALS INC | President & CEO | Form 4 sale | 105,452 | $4.5M | 42.5% | Unusual | SEC |
| May 16, 2012 | May 16, 2012 | CUBIST PHARMACEUTICALS INC | President and CEO | Form 4 sale | 4,245 | $178k | 2.8% | Plan not stated | SEC |
| May 14, 2012 | May 15, 2012 | CUBIST PHARMACEUTICALS INC | President and CEO | Form 4 sale | 2,927 | $122k | 2.0% | Plan not stated | SEC |
| Dec 20, 2011 | Dec 21, 2011 | CUBIST PHARMACEUTICALS INC | President and CEO | Form 4 sale | 150,000 | $5.8M | 52.6% | Unusual | SEC |
| Apr 22, 2010 | Apr 23, 2010 | CUBIST PHARMACEUTICALS INC | President and CEO | Form 4 sale | 184,548 | $4.2M | 75.4% | Unusual | SEC |